Premarketing Applications of Pharmacoepidemiology

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 391-400

  Guess, Harry A ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

Clinical trial planning contribution analysis; Cohort and case control study designs and postmarketing pharmacoepidemiology; Consolidated Standards for Reporting Trials (CONSORT statement); CONSORT statement online checklist; Drug development epidemiologic method application; FDA draft guidance on premarketing risk assessment; Information technology requirements; Pharmacoepidemiology premarketing application; Premarketing pharmacoepidemiology and premarketing risk assessment

Indexed keywords

EID: 33750476535     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch26     Document Type: Chapter

References (55)

1. Lawson DH. Pharmacoepidemiology: A new discipline. BMJ 1984;289:940-1.
2. Tilson HH. Pharmacoepidemiology: the future. Drug Intell Clin Pharm 1988;22:416-21.
3. Guess HA. Adverse and beneficial effects in pharmacoepidemiology. In: Armitage P, Colton T, eds, Encyclopedia of Biostatistics. New York: John Wiley & Sons, 1998; pp. 3332-8.
4. Guess HA, Stephenson WP, Sacks ST, Gardner JS. Beyond pharmacoepidemiology: the larger role of epidemiology in drug development. J Clin Epidemiol 1988;41:995-6.
5. Epstein RS, Feng W, Hirsch LJ, Kelly M. Intervention thresholds for the treatment of osteoporosis: comparison of different approaches to decision-making. Osteoporos Int 1998;8 (suppl 1): 22-7.
6. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995;155:477-81.
7. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;10:646-51.
8. O'Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA et al. A brief male sexual function inventory for urology. Urology 1995;46:697-706.
9. Coplan P, Chiacchierini L, Nikas A, Shea J, Baumritter A, Beutner K et al. Development and evaluation of a standardized questionnaire for identifying adverse events in vaccine clinical trials. Pharmacoepidemiol Drug Saf 2000;9:457-71.
10. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology 1997;104:334-42.
11. Lucky AW, Barber BL, Girman CJ, Williams J, Ratterman J, Waldstreicher J. A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 1996;35:559-65.
12. Ross PD, He YF, Davis JW, Epstein RS, Wasnich RD. Normal ranges for bone loss rates. Bone Miner 1994;26:169-80.
13. Hirsch LJ, Pryor-Tillotson S. An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women. Ann Ital Med Int 1995;10 (suppl): 22-8.
14. Rojas C, Coplan PM, Rhodes T, Robertson MN, DiNubile MJ, Guess HA. Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. Pharmacoepidemiol Drug Saf 2003;12:361-9.
15. West SL, Yawn BP, Thorp JM, Korhonen MJH, Savitz DA, Guess H. Tocolytic therapy for preterm labor: assessing its potential for reducing preterm delivery. Paediatr Perinat Epidemiol 2001;15:243-51.
16. Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia 1997;17:867-72.
17. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 2003;11:522-7.
18. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-32.
19. US Food and Drug Administration. Task Force on Risk Management. Managing the Risks from Medical Product Use- Creating a Risk Management Framework. May 1999, Part 4, p. 73. Available at: http://www.fda.gov/oc/tfrm/riskmanagement.pdf. Accessed: June 6, 2004.
20. US Food and Drug Administration. Guidance for Industry. Pre-marketing Risk Assessment. Draft Guidance. Available at: http://www.fda.gov/cder/guidance/5765dft.pdf. Accessed: June 6, 2004.
21. US Food and Drug Administration. Guidance for Industry. Development and Use of Risk Minimization Action Plans. Draft Guidance. Available at: http://www.fda.gov/cder/guidance/ 5766dft.pdf. Accessed: June 6, 2004.
22. US Food and Drug Administration. Guidance for Industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. Draft Guidance. Available at: http://www.fda.gov/ cder/guidance/5767dft.pdf. Accessed: June 6, 2004.
23. Streiner DL, Norman GR. Health Measurement Scales-A Practical Guide to their Development and Use, 3rd edn. New York: Oxford University Press, 2003.
24. Guyatt G, Rennie D. Users' Guides to the Medical Literature- A Manual for Evidence-Based Clinical Practice. Chicago, IL: AMA Press, 2001.
25. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New York: Oxford University Press, 2003.
26. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-62.
27. US Food and Drug Administration. Center for Drug Evaluation and Research. Conducting a Safety Review of a New Product Application and Preparing a Report on the Review. Available at: http://www.fda.gov/cder/guidance/issrvg08.pdf. Accessed: June 6, 2004.
28. Food and Drug Administration. Staff College. MedWatch Continuing Education Article-Clinical Therapeutics and the Recognition of Drug-Induced Disease. June 1995. Available at: http://www.fda.gov/medwatch/articles/dig/rcontent.htm. Accessed: June 6, 2004.
29. Hill AB. The environment and disease: association or causation. Proc R Soc Med 1965;58:295-300.
30. Guess HA. Invited commentary: vasectomy and prostate cancer. Am J Epidemiol 1990;132:1062-5.
31. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non- Life-Threatening Conditions, E1. ICH, 1994. Available at: http://www.ich.org.Accessed June 6, 2004.
32. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999;149:981-3.
33. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
34. Speirs CJ, Dollery CT, Inman WH, Rawson NS, Wilton LV. Postmarketing surveillance of enalapril. II: investigation of the potential role of enalapril in deaths with renal failure. BMJ 1988;297:830-2.
35. Badr KF, Ichikawa I. Prerenal failure: a deleterious shift from renal compensation to decompensation. N Engl J Med 1988;319:623-9.
36. Weed DL, Hursting SD. Biologic plausibility in causal inference: current method and practice. Am J Epidemiol 1998;147:415-25.
37. Lane DA. The Bayesian approach to causality assessment: an introduction. Drug Inf J 1986;20:455-61.
38. Hutchinson TA. Bayesian assessment of adverse drug reactions. Can Med Assoc J 2000;163:1463-4.
39. Guess HA. Behavior of the exposure odds ratio in a case control study when the hazard function is not constant over time. J Clin Epidemiol 1989;42:1179-84.
40. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20.
41. Yola M, Lucien A. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47:731-7.
42. Guess HA, Thomas JE. A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence density data. Epidemiology 1990;1:75-7.
43. Martin DO, Austin H. An exact method for meta-analysis of case-control and follow-up studies. Epidemiology 2000;11:255-60.
44. Greenland S, Rothman KJ. Introduction to stratified analysis. In: Rothman KJ, Greenland S, eds, Modern Epidemiology, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1998; pp. 253-79.
45. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning, 1982; p. 163.
46. Breslow NE, Day NE. Statistical Methods in Cancer Research, vol. II The Design and Analysis of Cohort Studies. International Agency for Research on Cancer Scientific Publication No. 82. Lyon, France: World Health Organization, 1987.
47. Girman CJ, Hartmaier S, Thiboutot D, Johnson J, Barber B, Demuro-Mercon C et al. Evaluating health-related quality of life in patients with facial acne: development of a selfadministered questionnaire for clinical trials. Qual Life Res 1996;5:481-90.
48. Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne-assessment of a new acne-specific questionnaire. Clin Exp Dermatol 2001;26:380-5.
49. Fehnel SE, McLeod LD, Brandman J, Arbit DI, McLaughlin-Miley CJ, Coombs JH et al. Responsiveness of the acne-specific quality of life questionnaire (acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res 2002;11:809-16.
50. Santanello NC, Demuro-Mercon C, Davies G, Ostrom N, Noonan M, Rooklin A et al. Validation of a pediatric asthma caregiver diary. J Allergy Clin Immunol 2000;106:861-6.
51. Santanello NC, Davies G, Galant SP, Pedinoff A, Sveum R, Seltzer J et al. Validation of an asthma symptom diary for interventional studies. Arch Dis Child 1999;80:414-20.
52. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988;84:911-18.
53. Guess HA, Resseguie LJ, Melton LJ III, Kurland LT, Lydick EG, Wilson WR. Factors predictive of seizures among intensive care unit patients with gram-negative infections. Epilepsia 1990;31:567-73.
54. US Food and Drug Administration. Drug Induced Liver Toxicity. Available at: http://www.fda.gov/cder/livertox/default. htm/. Accessed: June 6, 2004.
55. Senior JR, Tipping RW. Serum transaminase elevations alone lack specificity for detecting rare serious liver disease (abstract 1132). Hepatology 2003;38 (suppl 1): 701A.